KPIs & Operating Metrics(New)
Biologics And Drug Delivery Revenue By CategoryBiologics And Drug Delivery Revenue By Category AnnualBreakdown Of AssetsCapital Equipment And Software Revenue By CategoryCapital Equipment And Software Revenue By Category AnnualCost Of RevenueDeferred RevenueEmployee StatisticsFunctional Neurosurgery Navigation And Therapy Revenue By CategoryFunctional Neurosurgery Navigation And Therapy Revenue By Category AnnualGross Margin %Gross ProfitOpex As A % Of Total Revenue %OPEX SegregationProfitabilityProfitability %Profitability AnnualProfitability Annual %Property And Equipment, Net BreakdownRemaining Performance ObligationsRemaining Performance Obligations AnnualRevenue By Business Vertical AnnualRevenue By Business Vertical Annual %Revenue By SegmentRevenue By Segment %Revenue By Segment AnnualRevenue By Segment Annual %Revenue By Service LineRevenue By Service Line %Revenue By Service Line AnnualRevenue By Service Line Annual %
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

ClearPoint Neuro (CLPT) Cost Of Revenue (2018 - 2025)

ClearPoint Neuro's Cost of Revenue history spans 13 years, with the latest figure at $4.0 million for Q4 2025.

  • On a quarterly basis, Cost of Revenue rose 33.13% to $4.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $15.3 million, a 12.1% increase, with the full-year FY2025 number at $14.3 million, up 16.39% from a year prior.
  • Cost of Revenue hit $4.0 million in Q4 2025 for ClearPoint Neuro, up from $3.8 million in the prior quarter.
  • Over the last five years, Cost of Revenue for CLPT hit a ceiling of $4.0 million in Q4 2025 and a floor of $1.1 million in Q2 2021.
  • Historically, Cost of Revenue has averaged $2.8 million across 5 years, with a median of $2.9 million in 2023.
  • The widest YoY moves for Cost of Revenue: up 109.57% in 2022, down 19.34% in 2022.
  • Tracing CLPT's Cost of Revenue over 5 years: stood at $3.1 million in 2021, then fell by 19.34% to $2.5 million in 2022, then surged by 32.19% to $3.3 million in 2023, then fell by 10.1% to $3.0 million in 2024, then skyrocketed by 33.13% to $4.0 million in 2025.
  • Business Quant data shows Cost of Revenue for CLPT at $4.0 million in Q4 2025, $3.8 million in Q3 2025, and $3.7 million in Q2 2025.